CLINICAL TRIALS PROFILE FOR FACTOR XIII CONCENTRATE (HUMAN)
✉ Email this page to a colleague
All Clinical Trials for factor xiii concentrate (human)
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000717 ↗ | The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | To determine the safety and effectiveness of clindamycin and primaquine in the treatment of mild Pneumocystis carinii pneumonia (PCP) in AIDS patients. As many as 80 percent of AIDS patients experience at least one episode of PCP and about one-third of these patients have a recurrence of the disease. Drugs currently used for treatment of acute PCP are toxic to the majority of AIDS patients. The combination of clindamycin and primaquine reduces the numbers of PCP organisms in laboratory tests and in animal studies. Both drugs can be given orally, concentrate in lung tissue, and have been used safely in humans for treatment of other diseases. It is possible that the combination may prove to be as good or better than standard therapy for PCP and side effects may be less. |
| NCT00002386 ↗ | Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 1969-12-31 | The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia. |
| NCT00004667 ↗ | Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease | Completed | University of North Carolina | Phase 1 | 1993-10-01 | OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients. |
| NCT00004667 ↗ | Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease | Completed | National Center for Research Resources (NCRR) | Phase 1 | 1993-10-01 | OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients. |
| NCT00004801 ↗ | Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency | Completed | University of North Carolina | Phase 1/Phase 2 | 1992-03-01 | OBJECTIVES: Assess the safety and long-term efficacy of monoclonal factor IX concentrate in patients with factor IX deficiency. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for factor xiii concentrate (human)
Condition Name
Clinical Trial Locations for factor xiii concentrate (human)
Trials by Country
Clinical Trial Progress for factor xiii concentrate (human)
Clinical Trial Phase
Clinical Trial Sponsors for factor xiii concentrate (human)
Sponsor Name
